
Lars Jakobsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3603718/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early vascular healing after implantation of the polymer-free biolimus-eluting stent or the ultrathin strut biodegradable polymer sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction. Coronary Artery Disease, 2022, Publish Ahead of Print, .	0.7	0
2	Impact of diabetes on 1â€year clinical outcome in patients undergoing revascularization with the BioFreedom stents or the Orsiro stents from the SORT OUT IX trial. Catheterization and Cardiovascular Interventions, 2022, , .	1.7	0
3	Comparison of MynxGrip vascular closure device and manual compression for closure after femoral access angiography: a randomized controlled trial: the closure devices used in every day practice study, CLOSE-UP III trial. BMC Cardiovascular Disorders, 2022, 22, 68.	1.7	9
4	5-Year Outcomes of PCI Guided by Measurement of Instantaneous Wave-Free Ratio Versus Fractional FlowÂReserve. Journal of the American College of Cardiology, 2022, 79, 965-974.	2.8	30
5	Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibodyâ€covered sirolimusâ€eluting Combo stentÂand the sirolimusâ€eluting Orsiro stent. Catheterization and Cardiovascular Interventions, 2022, , .	1.7	2
6	Polymer-free biolimus-coated stents versus ultrathin-strut biodegradable polymer sirolimus-eluting stents: two-year outcomes of the randomised SORT OUT IX trial. EuroIntervention, 2022, 18, e124-e131.	3.2	7
7	Long-Term Outcomes of Perioperative Versus Nonoperative Myocardial Infarction: A Danish Population-Based Cohort Study (2000–2016). Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	2.2	1
8	Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial. Circulation, 2021, 143, 2155-2165.	1.6	25
9	Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation, 2021, 144, 1476-1484.	1.6	121
10	Agreement between nonculprit stenosis follow-up iFR and FFR after STEMI (iSTEMI substudy). BMC Research Notes, 2020, 13, 410.	1.4	4
11	Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention. Circulation, 2020, 141, 2052-2063.	1.6	48
12	Instantaneous wave-free ratio cutoff values for nonculprit stenosis classification in patients with ST-segment elevation myocardial infarction (an iSTEMI substudy). Coronary Artery Disease, 2020, 31, 411-416.	0.7	1
13	Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2020, 39, 371-378.	0.6	13
14	Culprit lesion morphology in patients with ST-segment elevation myocardial infarction assessed by optical coherence tomography. Coronary Artery Disease, 2020, 31, 671-677.	0.7	0
15	Procedural findings and early healing response after implantation of a self-apposing bioresorbable scaffold in coronary bifurcation lesions. International Journal of Cardiovascular Imaging, 2019, 35, 1199-1210.	1.5	5
16	Quantitative flow ratio for immediate assessment of nonculprit lesions in patients with STâ€segment elevation myocardial infarction—An iSTEMI substudy. Catheterization and Cardiovascular Interventions, 2019, 94, 686-692.	1.7	45
17	Randomized Comparison of Terumo® Coated Slender™ versus Terumo® Noncoated Traditional Sheath during Radial Angiography or Percutaneous Coronary Intervention. Journal of Interventional Cardiology, 2019, 2019, 1-7.	1.2	1
18	Impact of diabetes on clinical outcomes after revascularization with sirolimusâ€eluting and biolimusâ€eluting stents with biodegradable polymer from the SORT OUT VII trial. Catheterization and Cardiovascular Interventions, 2019, 93, 567-573.	1.7	11

Lars Jakobsen

#	Article	IF	CITATIONS
19	Evaluation of Coronary Artery Stenosis by Quantitative Flow Ratio During Invasive Coronary Angiography. Circulation: Cardiovascular Imaging, 2018, 11, e007107.	2.6	157
20	Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents: the SORT-OUT VII optical coherence tomography study. European Heart Journal Cardiovascular Imaging, 2018, 19, 329-338.	1.2	5
21	Computed tomography derived fractional flow reserve testing in stable patients with typical angina pectoris: influence on downstream rate of invasive coronary angiography. European Heart Journal Cardiovascular Imaging, 2018, 19, 405-414.	1.2	45
22	Short- and Long-Term Mortality and Stroke Risk After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2018, 121, 78-85.	1.6	15
23	Detection of early changes in the coronary artery microstructure after heart transplantation: A prospective optical coherence tomography study. Journal of Heart and Lung Transplantation, 2018, 37, 486-495.	0.6	23
24	Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2018, 11, 1437-1449.	2.9	111
25	Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X trial. American Heart Journal. 2018. 202. 49-53.	2.7	12
26	Coronary CT Angiographic and Flow Reserve-Guided Management of Patients With Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2018, 72, 2123-2134.	2.8	138
27	Design and rationale for the I nfluenza vaccination A fter M yocardial I nfarction (IAMI) trial. A registry-based randomized clinical trial. American Heart Journal, 2017, 189, 94-102.	2.7	39
28	Severe Mental Illness and Clinical Outcome After Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 120, 550-555.	1.6	21
29	Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. New England Journal of Medicine, 2017, 376, 1813-1823.	27.0	740
30	Myocardial Infarction in Adults With Congenital Heart Disease. American Journal of Cardiology, 2017, 120, 2272-2277.	1.6	38
31	Nonculprit Stenosis Evaluation Using Instantaneous Wave-Free Ratio in PatientsÂWith ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2017, 10, 2528-2535.	2.9	55
32	Final five-year outcomes after implantation of biodegradable polymer-coated biolimus-eluting stents versus durable polymer-coated sirolimus-eluting stents. EuroIntervention, 2017, 13, 1336-1344.	3.2	11
33	TCT-261 Impact of Diabetes on Clinical Outcomes after Revascularization with Sirolimus-eluting and Birolimus-Eluting Stents with biodegradable polymer. From the SORT OUT VII Trial. Journal of the American College of Cardiology, 2016, 68, B106.	2.8	0
34	Age- and sex-related differences in use of guideline-recommended care and mortality among patients with incident heart failure in Denmark. Age and Ageing, 2016, 45, 635-641.	1.6	8
35	Hospital-diagnosed atopic dermatitis and long-term risk of myocardial infarction: a population-based follow-up study. BMJ Open, 2016, 6, e011870.	1.9	24
36	Dimensions of Socioeconomic Status and Clinical Outcome After Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2012, 5, 641-648.	3.9	46

#	Article	IF	CITATIONS
37	Sex- and age-related differences in clinical outcome after primary percutaneous coronary intervention. EuroIntervention, 2012, 8, 904-911.	3.2	31
38	Comparison of Primary Percutaneous Coronary Intervention in Real-World Populations Versus Clinical Trial Populations. American Journal of Cardiology, 2010, 105, 1684-1691.	1.6	2